Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Reported by Ars Technica.
This story is developing. Read the full report from Ars Technica.
Original reporting
This brief was written with AI assistance from the reports listed above and checked against our editorial policy. Spotted an error? Request a correction.